Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 617-328-0 | CAS number: 82391-37-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Skin sensitisation - in vitro (waiver)
According to Annex VII, column 2, standard information requirement 8.3.1, an in vitro skin sensitisation study does not need to be conducted if an in vivo study according to point 8.3.2 is available. Column 2, point 8.3.2 states that in vivo skin sensitisation studies that were carried out or initiated before 10 May 2017, and that meet the requirements set out in Article 13(3), first subparagraph, and Article 13(4) shall be considered appropriate to address this standard information requirement. Additionally, the murine local lymph node assay (LLNA) is the first- choice method for in vivo testing. Only in exceptional circumstances should another test be used. Justification for the use of another in vivo test shall be provided.
In the present case, a suitable guinea pig maximisation test (Skin sensitisation - Maximisation Test. Takahashi (2001)) is available, which meets the requirements set out in Article 13(3), first subparagraph, and Article 13(4). Additionally, the original Test Guideline (TG) for the determination of skin sensitisation in the mouse, the Local Lymph Node Assay (LLNA; TG 429) was adopted in 2002. Therefore, the LLNA method was not available by the time this guinea pig maximisation test (Skin sensitisation - Maximisation Test. Takahashi (2001)) was conducted (study period: 1 December 2000 to 30 December 2000).
Skin sensitisation - Maximisation Test. Takahashi (2001)
Under the conditions of this study, the test material was found not to be sensitising to the skin.
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1 December 2000 to 30 December 2000
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Version / remarks:
- 17 July 1992
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- guinea pig maximisation test
- Justification for non-LLNA method:
- The original Test Guideline (TG) for the determination of skin sensitisation in the mouse, the Local Lymph Node Assay (LLNA; TG 429) was adopted in 2002. Therefore, the LLNA method was not available by the time this study was conducted (study period: 1 December 2000 to 30 December 2000).
- Species:
- guinea pig
- Strain:
- Hartley
- Sex:
- male
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Females (if applicable) nulliparous and non-pregnant: not applicable
- Age at study initiation: 4 weeks old
- Weight at study initiation: 299 to 356 g (preliminary study), 289 to 328 g (main study)
- Housing: Animals were housed 1 or 2 per aluminum cage (38 cm [D] x 30 cm [W] x 18 cm [H]) with bedding in the SPF animal facility guinea pig study room.
- Diet: Approximately 25 g of irradiated sterilised solid food for guinea pigs was provided once daily to each animal. Each lot of food was analysed, and it was confirmed that there were no problems.
- Water: Water conforming to the quality standards in the Japanese Water Supply Act was available ad libitum in 200 mL water bottles. Water was analysed regularly and it was confirmed that there were no problems.
- Acclimation period: 10 days (preliminary study), 7 days (main study)
- Animal health: During the 7-day quarantine and acclimation period, the animals were observed for clinical signs once daily and weighed once on the first and
final days. Twenty males that showed no abnormalities were used (main study).
ENVIRONMENTAL CONDITIONS
- Temperature (°C): Temperature in the room was set at 22 ± 2°C (actual range: 20.5 to 23.8°C, acceptable range: 18 to 26°C)
- Humidity (%): Humidity set at 50 ± 10% (actual range: 39 to 64%, acceptable range: 30 to 70%),
- Air changes (per hr): 15 times/hour
- Photoperiod (hrs dark / hrs light): 12 hours of artificial light per day (lights on from 6:00 am to 6:00 pm)
- Additional information: The study room was cleaned daily, and the cages, bedding, water bottles, and food containers were exchanged twice weekly for autoclaved (121°C, 30 minutes) replacements. - Route:
- intradermal
- Vehicle:
- unchanged (no vehicle)
- Concentration / amount:
- 100 vol%. 0.1 mL/site
- Adequacy of induction:
- highest technically applicable concentration used
- Route:
- epicutaneous, semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Concentration / amount:
- 100 vol%, filter papers (2 x 4 cm) loaded with 0.2 mL of preparation were applied
- Day(s)/duration:
- Topical induction begins 7 days after intradermal induction. Exposure duration: 48 hours
- Adequacy of induction:
- non-irritant substance, but skin pre-treated with 10% SDS
- No.:
- #1
- Route:
- epicutaneous, semiocclusive
- Vehicle:
- water
- Remarks:
- water for injection
- Concentration / amount:
- 100 (undiluted solution), 10, 1, 0.1, and 0.01 vol% concentrations. 1.5 x 1.5 cm filter papers loaded with 0.1 mL/site of 100, 10, 1, 0.1, and 0.01 w/v% test article preparations were applied
- Day(s)/duration:
- Challenge exposure occurred 12 days after topical induction. Exposure duration: 24 hours
- Adequacy of challenge:
- highest non-irritant concentration
- No. of animals per dose:
- The study design consisted of 1 test article group, 1 negative control group, and 1 positive control group (total: 3 groups). 10 animals for the test article group and 5 animals each for the negative and positive control groups were selected.
In the test article and negative control article groups, 100, 10, 1, 0.1, and 0.01 w/v% test article preparations were applied to sites D to H (see illustration included in 'Overall remarks, attachments' section) and a 1.5 x 1.5 cm filter paper loaded with water for injection was applied to site I. Therefore, each animal in the test article (10 animals) and negative control article (5 animals) groups was exposed to 5 different concentrations as well as water for injection only during challenge. - Details on study design:
- PRELIMINARY STUDY:
- Study Design and Identification of Animals:
The study consisted of 2 groups. On the final day of the quarantine and acclimation period (November 30, 2000), 6 animals were selected randomly for each group. The animals were identified by marking with dye during examination, and cages were identified by color-coded cage cards (indicating the study number, group number, and animal number). The study design is shown in Table 'Preliminary Study Design'.
- Study Method - Intradermal Dosing Group:
The back of each animal was shaved, and 0.1 mL each of the 100, 75, 50, 25, 10, and 5 vol% test article preparations was administered once intradermally with a disposable syringe and needle to the back of 2 guinea pigs (single dose).
- Study Method - Percutaneous Dosing Group:
The back of each animal was shaved, and filter papers (1.5 x 1.5 cm) which had been loaded with 0.2 mL of 100, 75, 50, 25, 10, and 5 vol% test article preparation had been applied were applied to 2 guinea pigs. The filter papers were then covered with Parafilm, secured with gauze and adhesive tape, and covered with a bandage once (single dose) for 24 hours.
- Clinical Signs Observation:
Clinical signs and mortality were observed once daily from the dosing day until the final day of observation in all animals. Clinical signs were observed once before and once after dosing on the dosing day.
- Evaluation:
Skin reaction was evaluated in accordance with the Draize method criteria.(1) The intradermal induction concentration for the main study was set at the highest concentration at which no eschar was observed. The lowest concentration at which erythema was observed was taken as the topical induction concentration. The highest concentration at which no erythema was observed was taken as the challenge concentration. See Table 'Criteria for the Evaluation of Skin Reaction' for further details.
MAIN STUDY
- Study Design and Identification of Animals:
The study design consisted of 1 test article group, 1 negative control group, and 1 positive control group (total: 3 groups). On the day before intradermal induction (December 4, 2000), animals were randomly assigned by stratified randomization according to body weight; 10 animals for the test article group and 5 animals each for the negative and positive control groups were selected. The animals were identified by marking with dye during the quarantine and acclimation period and by ear punching after grouping. Cages were identified by color-coded cage cards (indicating the study number, group number, and animal number). See Table 'Main Study Design' for further details.
- Justification for Selection of the Dose Concentration:
As a result of the preliminary study, eschar was not observed in the intradermal dosing group at any concentration. Therefore, the intradermal induction concentration in the main study was set at 100 vol%. In the percutaneous dosing group, no erythema was observed at any concentration. Therefore, the topical induction concentration was set at 100 vol%, and the challenge concentration was set at 100 vol% (undiluted solution) as the highest concentration, at 10, 1, 0.1 and 0.01 vol% in a common ratio of 10.
- Clinical Signs Observation:
Clinical signs and mortality were observed once daily from the first day of induction until the final day of observation in all animals. Clinical signs were observed once before and once after dosing on the days of intradermal induction, topical induction, and challenge dosing.
A. INDUCTION EXPOSURE
- Intradermal Induction:
The induction sites on the dorsal scapular region of the guinea pig were shaved to a size of 4 x 6 cm with electric hair clippers (0.5 mm blade) on the day before dosing, and the 3 preparations stated below were injected once (single dose) intradermally with a disposable syringe and needle at a volume of 0.1 mL/site to the left and right sides at paired sites A, B, and C.
A: 1:1 W/O emulsion of water for injection and FCA
B: Test article preparation (Group 1: Vehicle-1, Group 2: Test material preparation, Group 3: 0.1 w/v% DNCB solution)
C: Test article or control article-FCA mixture (Group 1: W/O emulsion of vehicle-1 and FCA, Group 2: W/O emulsion of test material preparation and FCA, Group 3: W/O emulsion of 0.2 w/v% DNCB solution and FCA)
- Topical Induction:
The same area as for intradermal induction was shaved 7 days after intradermal induction. 10% Sodium lauryl sulfate ointment (0.5 g) as an inflammatory agent was administered by direct application at the intradermal induction sites. The inflammatory agent was removed after 24 hours, and filter papers (2 x 4 cm) loaded with 0.2 mL of preparation were applied. The filter papers were then covered with Parafilm, secured with gauze and adhesive tape, and covered with a bandage for 48 hours. The frequency and period was counted as one (single) dosing.
B. CHALLENGE EXPOSURE
For the challenge sites, areas approximately 8 cm wide on the left and right abdomen, as shown in the illustration included in 'Overall remarks, attachments' section, were shaved with electric clippers 11 days after topical induction. On the following day (12 days after topical induction), 1.5 x 1.5 cm filter papers loaded with 0.1 mL/site of 100, 10, 1, 0.1, and 0.01 w/v% test article preparations were applied to sites D to H and a 1.5 x 1.5 cm filter paper loaded with water for injection was applied to site I in the test article and negative control article groups. In the positive control article group, a 1.5 x 1.5 cm filter paper loaded with 0.1 mL/site of 0.1 w/v% DNCB solution was applied to site E. The filter papers were then covered with Parafilm, secured with gauze and adhesive tape, and covered with a bandage for 24 hours. The frequency and period was counted as one (single) dosing.
- Evaluation (hr after challenge):
Skin reaction at 24 and 48 hours after challenge was determined. Skin reaction was evaluated in accordance with the Draize method criteria.(1) See Table 'Criteria for the Evaluation of Skin Reaction' for further details. Photographs were taken of one representative animal per group.
- Body Weight:
Animals were weighed on the evaluation day of 48 hours after challenge.
JUSTIFICATION FOR SELECTION OF THE DOSING ROUTE, VOLUME, METHOD, FREQUENCY AND PERIOD
Dosing route, volume, method, frequency, and period for intradermal induction, topical induction, and challenge were all in accordance with the OECD Guidelines for Testing of Chemicals 406 (Skin Sensitisation, adopted: 17th July 1992).
TREATMENT OF ANIMALS
Surplus animals after grouping and study animals after completion of macroscopic observations were euthanized by an intraperitoneal injection of 4 mL/body of sodium pentobarbital (Tokyo Kasei Kogyo Co., Ltd.) solution (64.8 mg/mL).
EVALUATION OF RESULTS AND STATISTICAL ANALYSIS
Statistical analysis was not performed.
References:
(1) Draize JH, Woodard G, and Calvery H. 0.: Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J. Pharmacol. Exp. Ther.;82:377-390, 1944 - Positive control substance(s):
- yes
- Remarks:
- 2,4-Dinitrochlorobenzene (DNCB)
- Positive control results:
- In the positive control group, erythema/eschar scored as 3 or 4 and edema scored as 4 was observed 24 or 48 hours after challenge. The mean reaction score 24 hours after challenge was 7.2. The mean reaction score 48 hours after challenge was 7.6.
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 0%
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Clinical observations:
- No abnormalities were noted in clinical signs or body weight change in any animal in any group during the observation period.
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 0%
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Clinical observations:
- No abnormalities were noted in clinical signs or body weight change in any animal in any group during the observation period.
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 100%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- No abnormalities were noted in clinical signs or body weight change in any animal in any group during the observation period.
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 100%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- No abnormalities were noted in clinical signs or body weight change in any animal in any group during the observation period.
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- positive control
- Dose level:
- 0.1%
- No. with + reactions:
- 5
- Total no. in group:
- 5
- Clinical observations:
- No abnormalities were noted in clinical signs or body weight change in any animal in any group during the observation period.
- Remarks on result:
- positive indication of skin sensitisation
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- positive control
- Dose level:
- 0.1%
- No. with + reactions:
- 5
- Total no. in group:
- 5
- Clinical observations:
- No abnormalities were noted in clinical signs or body weight change in any animal in any group during the observation period.
- Remarks on result:
- positive indication of skin sensitisation
- Interpretation of results:
- other: Not classified according to EU criteria.
- Conclusions:
- Under the conditions of this study, the test material was found not to be sensitising to the skin.
- Executive summary:
The skin sensitisation potential of the test material was investigated in guinea pigs using the maximisation method according to OECD guideline 406 and in compliance with GLP. A guinea maximisation study was performed, as opposed to a LLNA study, because the LLNA method was not available by the time this study was conducted (study period: 1 December 2000 to 30 December 2000).
In the test article group, 100, 10, 1, 0.1, and 0.01 w/v% of the test material and water for injection were applied to guinea pigs sensitised intradermally and by topical application for 24 hours. The challenge sites were observed 24 and 48 hours after challenge. In the negative control group, water for injection was injected intradermally and applied topically, and the animals were challenged in the same manner as those in the test material group. In the positive control group, 0.1 w/v% DNCB solution was injected intradermally and applied topically, and the animals were challenged with 0.1 w/v% DNCB solution.
In the test material group, no abnormalities were observed at any challenge site in all animals at any observation point. In the negative control group, no abnormalities were observed at any challenge site at any observation point. In the positive control group, clear positive reactions (erythema/eschar and edema) were observed at all observation points.
Under the conditions of this study, the test material was found not to be sensitising to the skin.
- Endpoint:
- skin sensitisation: in vitro
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- an in vitro skin sensitisation study does not need to be conducted because adequate data from an in vivo skin sensitisation study are available
- Justification for type of information:
- JUSTIFICATION FOR DATA WAIVING
According to Annex VII, column 2, standard information requirement 8.3.1, an in vitro skin sensitisation study does not need to be conducted if an in vivo study according to point 8.3.2 is available. Column 2, point 8.3.2 states that in vivo skin sensitisation studies that were carried out or initiated before 10 May 2017, and that meet the requirements set out in Article 13(3), first subparagraph, and Article 13(4) shall be considered appropriate to address this standard information requirement. Additionally, the murine local lymph node assay (LLNA) is the first- choice method for in vivo testing. Only in exceptional circumstances should another test be used. Justification for the use of another in vivo test shall be provided.
In the present case, a suitable guinea pig maximisation test (Skin sensitisation - Maximisation Test. Takahashi (2001)) is available, which meets the requirements set out in Article 13(3), first subparagraph, and Article 13(4). Additionally, the original Test Guideline (TG) for the determination of skin sensitisation in the mouse, the Local Lymph Node Assay (LLNA; TG 429) was adopted in 2002. Therefore, the LLNA method was not available by the time this guinea pig maximisation test (Skin sensitisation - Maximisation Test. Takahashi (2001)) was conducted (study period: 1 December 2000 to 30 December 2000).
Referenceopen allclose all
Mean Reaction Scores
Group | Number of animals | Treatment | Score* | |||||||
Induction | Challenge | 24 hours** | 48 hours** | |||||||
lntradermal injection | Topical application | Erythema | Edema | Total | Erythema | Edema | Total | |||
1 | 5 | Water for injection | Water for injection | Water for injection | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
0.01 % Test material | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||||
0.1% Test material | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||||
1 % Test material | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||||
10% Test material | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||||
100% Test material | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||||
2 | 10 | Test material | Test material | Water for injection | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
0.01 % Test material | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||||
0.1% Test material | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||||
1 % Test material | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||||
10% Test material | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||||
100% Test material | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||||
3 | 5 | 0.1% DNCB | 0.1% DNCB | 0.1% DNCB | 3.2 | 4.0 | 7.2 | 3.6 | 4.0 | 7.6 |
* Total irritation score/number of animals
** Time (hour) after the removal of challenge
Erythema: Erythema and eschar
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (sensitising)
Justification for classification or non-classification
In accordance with the criteria for classification as defined in Annex I, Regulation (EC) No 1272/2008, the substance does not require classification with respect to skin sensitisation.
In accordance with Annex VI, regulation (EC) No 1272/2008, the substance does require classification with respect to respiratory sensitisation - Category 1: H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.